2 completed, 1 suspended, 1 terminated, 1 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 1, Suspended 1, Terminated 1, Withdrawn 1 |
Follow lucitanib: new trials by email Literature Review of lucitanib trials Research Report on lucitanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy nivolumab, ipilimumab, cabozantinib - Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Bristol-Myers Squibb | 2021-04-15 | 2023-12-19 | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor Lucitanib, Nivolumab - Advanced Solid Tumor, Gynecologic Cancer | Phase 1 / Phase 2 | Suspended | Clovis Oncology, Inc. | 227 | 2019-07-29 | 2022-12-20 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer | Phase 1 / Phase 2 | Terminated | pharmaand GmbH | 25 | 2019-06-28 | 2024-01-16 |
| Study of the AL3810 in the Treatment of Advanced Solid Tumor Lucitanib - Advanced Solid Tumors | Phase 1 | Completed | Haihe Biopharma Co., Ltd. | 17 | 2014-03-01 | 2017-04-17 |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Lucitanib - Solid Tumors | Phase 1 / Phase 2 | Completed | Institut de Recherches Internationales Servier | 134 | 2010-07-01 | 2024-07-25 |
Ovarian Neoplasms (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Genital Neoplasms, Female (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Bristol-Myers Squibb (1) · Clovis Oncology, Inc. (1) · Haihe Biopharma Co., Ltd. (1) · Institut de Recherches Internationales Servier (1) · pharmaand GmbH (1)
United States (3) · Belgium (2) · Italy (2) · Spain (2) · Argentina (1) · Austria (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Mexico (1) · Netherlands (1) · Norway (1) · Poland (1)
Erika Hamilton, MD (1) · Jin Li, M.D. (1) · Junning Cao, M.D. (1) · Nicole Concin, MD (1)
2018 (2)